Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax’ prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalent vaccine utilizing Novavax’ recombinant protein/adjuvant technology Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to […]

9 พ.ย. 65

EIT Health’s Venture Centre of Excellence Names ProductLife Group as Privileged Partner for Regulatory & Compliance

The ambitious EU initiative has already secured 2 billion euros of co-investment capabilities and has supported 60 innovative Biotech, Medtech & digital health start-ups to get to market or expand into new territories. EIT Health, co-operator of the Venture Centre of Excellence alongside the European Investment Fund (EIF), has named ProductLife Group the exclusive Privileged […]

8 พ.ย. 65

What are stem cells?

Stem cells are the body’s raw materials — cells from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. These daughter cells become either new stem cells or specialized cells (differentiation) with a more specific […]

4 พ.ย. 65

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of myelofibrosis (MF). Selinexor was granted orphan drug designation in MF by the…

3 พ.ย. 65

AstraZeneca’s long-acting antibody (LAAB) combination granted conditional marketing approval for the treatment of COVID-19 in Thailand

AstraZeneca’s AZD7442 (tixagevimab and cilgavimab), a long-acting antibody combination (LAAB), has been granted conditional marketing approval in Thailand for the treatment of mild to moderate COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg). This approval is in addition to the conditional marketing approval granted to LAAB by […]

2 พ.ย. 65

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

United States-based National Comprehensive Cancer Network enters strategic cooperation agreement with Chinese medical information website to publish and translate evidence-based expert consensus guidelines for cancer care; now available at The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is announcing a new collaboration with Medlive to share NCCN Clinical Practice…

2 พ.ย. 65

Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.

Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. Lo.Li. Pharma International announces the pre-launch of a new, highly anticipated product at CPHI 2022, fulfilling a […]

2 พ.ย. 65
1 2 3 4 5 76